nifedipine has been researched along with Cardiovascular Diseases in 96 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective analysis of the database from A Coronary Disease Trial Investigating Outcome with Nifedipine (ACTION) evaluated the effectiveness of nifedipine gastrointestinal therapeutic system (GITS) (i) in combination with renin angiotensin system (RAS) blockers and (ii) in patients with isolated systolic hypertension (ISH)." | 9.15 | Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. ( Elliott, HL; Meredith, PA, 2011) |
| "The Japan Multicenter Investigation for Cardiovascular Diseases-B was performed to investigate whether nifedipine retard treatment was associated with a significantly higher incidence of cardiac events than angiotensin converting enzyme inhibitor treatment in Japanese patients." | 9.11 | Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. ( Arakawa, K; Hirayama, A; Hosoda, S; Iimura, O; Ishii, M; Kanmatsuse, K; Kawai, C; Kodama, K; Nonogi, H; Origasa, H; Saruta, T; Sumiyoshi, T; Yui, Y, 2004) |
| "The International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT) showed, by means of office blood pressure measurements, that long-term treatment with nifedipine GITS is as effective as diuretics in preventing cardiovascular and cerebrovascular complications." | 9.10 | Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Mancia, G; Omboni, S; Parati, G, 2002) |
| "To investigate the impact of treatment on cardiovascular mortality and morbidity, we assessed outcomes in patients with hypertension and diabetes who received co-amilozide or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension." | 9.10 | Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). ( Brown, M; Castaigne, A; de Leeuw, P; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM; Wagener, G, 2003) |
| " Among these trials, the International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) is of special interest because it is the first study to address, in a prospective fashion, the prognostic influence of antihypertensive treatment (nifedipine GITS vs a combined thiazide and potassium-sparing diuretic) in hypertensive patients with concomitant risk factors such as hypercholesterolemia, cigarette smoking, diabetes, and left ventricular hypertrophy." | 9.08 | The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. ( Grassi, G; Mancia, G, 1998) |
| "To ascertain the baseline characteristics of the high-risk hypertensive patients entering the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT)." | 9.08 | Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Rosenthal, T; Ruilope, LM, 1998) |
| "Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent." | 6.45 | Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. ( Beckey, C; Lundy, A; Lutfi, N, 2009) |
| "High blood pressure is the most prevalent cardiovascular risk factor and, in clinical practice, coronary disease and hypertension often occur concurrently." | 6.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| "Nisoldipine is an orally administered calcium entry blocking drug structurally related to nifedipine." | 6.37 | Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. ( Friedel, HA; Sorkin, EM, 1988) |
| "In the treatment of preterm labor, the combination regimen of ritodrine and nifedipine can be more effective than ritodrine alone for prolonging gestation over seven days." | 5.40 | The influence of ritodrine alone or in combination with nifedipine on maternal cardiovascular side effects and pregnancy outcomes. ( Bae, JY; Hwang, I; Kim, MJ; Seong, WJ, 2014) |
| " Once-daily dosing with nifedipine GITS has been shown to achieve smooth and continuous blood pressure control, identical to conventional first-line diuretic therapy." | 5.33 | Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes. ( Heagerty, AM, 2005) |
| "It is revealed that only nifedipine CR and cilnidipine could reduce albuminuria statistically." | 5.17 | A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers. ( Arakawa, K; Fujii, M; Inoki, I; Kimura, T; Konoshita, T; Makino, Y; Miyamori, I; Morikawa, N; Nakamura, H; Wakahara, S, 2013) |
| " We conducted a randomized, double-blind, three-way crossover study in 27 patients with proteinuric CKD to compare the effects of the ET(A) receptor antagonist sitaxentan, nifedipine, and placebo on proteinuria, BP, arterial stiffness, and various cardiovascular biomarkers." | 5.17 | Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. ( Blackwell, S; Dhaun, N; Goddard, J; Johnston, NR; Melville, V; Talwar, DK; Webb, DJ, 2013) |
| "A retrospective analysis of the database from A Coronary Disease Trial Investigating Outcome with Nifedipine (ACTION) evaluated the effectiveness of nifedipine gastrointestinal therapeutic system (GITS) (i) in combination with renin angiotensin system (RAS) blockers and (ii) in patients with isolated systolic hypertension (ISH)." | 5.15 | Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. ( Elliott, HL; Meredith, PA, 2011) |
| "Data from a trial comparing long-acting nifedipine gastrointestinal therapeutic system to placebo in 7,665 patients with stable angina pectoris was analyzed." | 5.12 | Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data. ( de Brouwer, S; Dunselman, PH; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; van Dalen, FJ; Vokó, Z, 2007) |
| "The Japan Multicenter Investigation for Cardiovascular Diseases-B was performed to investigate whether nifedipine retard treatment was associated with a significantly higher incidence of cardiac events than angiotensin converting enzyme inhibitor treatment in Japanese patients." | 5.11 | Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. ( Arakawa, K; Hirayama, A; Hosoda, S; Iimura, O; Ishii, M; Kanmatsuse, K; Kawai, C; Kodama, K; Nonogi, H; Origasa, H; Saruta, T; Sumiyoshi, T; Yui, Y, 2004) |
| "The International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT) showed, by means of office blood pressure measurements, that long-term treatment with nifedipine GITS is as effective as diuretics in preventing cardiovascular and cerebrovascular complications." | 5.10 | Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Mancia, G; Omboni, S; Parati, G, 2002) |
| "To investigate the impact of treatment on cardiovascular mortality and morbidity, we assessed outcomes in patients with hypertension and diabetes who received co-amilozide or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension." | 5.10 | Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). ( Brown, M; Castaigne, A; de Leeuw, P; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM; Wagener, G, 2003) |
| "To ascertain the baseline characteristics of the high-risk hypertensive patients entering the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT)." | 5.08 | Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Rosenthal, T; Ruilope, LM, 1998) |
| " Among these trials, the International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) is of special interest because it is the first study to address, in a prospective fashion, the prognostic influence of antihypertensive treatment (nifedipine GITS vs a combined thiazide and potassium-sparing diuretic) in hypertensive patients with concomitant risk factors such as hypercholesterolemia, cigarette smoking, diabetes, and left ventricular hypertrophy." | 5.08 | The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. ( Grassi, G; Mancia, G, 1998) |
| " We, along with others, have recently found that nifedipine, one of the most widely used DHPs, inhibits apoptotic cell death of endothelial cells (ECs) as well as vascular inflammation and subsequently improves endothelial function in patients with cardiovascular risk factors, including hypertension and/or diabetes, thus slowing the development and progression of atherosclerosis in these patients." | 4.84 | Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. ( Matsui, T; Nakamura, K; Yamagishi, S, 2008) |
| " The International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) is the first, large, randomized, double-blind study undertaken exclusively in high-risk hypertensive patients, with CV events as a prospectively defined primary end-point." | 4.81 | Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS? ( Ruilope, LM, 2002) |
| "The data from The International Nifedipine Intervention as a Goal in Hypertension Treatment (INSIGHT) Study indicate that effectively reducing blood pressure can decrease the incidence of cardiovascular events in high risk patients with concomitant pathology, including diabetes and hypercholesterolemia, as well as in smokers and those with poor family history." | 4.81 | Role of calcium channel blockers in the future, in view of the INSIGHT Study. ( Rosenthal, T, 2002) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| " As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function." | 4.77 | Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications. ( Katz, AM; Leach, NM, 1987) |
| " Patients with hypertension (ie, blood pressure [BP] >140/90 mm Hg, or >130/80 mm Hg in patients at high or very high cardiovascular risk) received once-daily nifedipine GITS (30, 60 or 90 mg) in combination with another antihypertensive or as add-on to existing therapy." | 3.81 | Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE). ( Dello, Z; Hussain, W; Motaweih, AK; Petri, T; Schmidt, B; Usova, E, 2015) |
| "6 years, 54% men), a subgroup of 544 participants in the calcification side arm of the INSIGHT (International Nifedipine Study Intervention as Goal for Hypertension Therapy)." | 3.79 | Progression of coronary artery calcification is associated with long-term cardiovascular events in hypertensive adults. ( Apter, S; Grossman, C; Grossman, E; Morag-Koren, N; Motro, M; Shemesh, J, 2013) |
| "Verapamil, which has profound electrophysiologic effects on the slow inward current, is emerging as a valuable antiarrhythmic agent." | 3.75 | Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. ( Antman, EM; Braunwald, E; Muller, JE; Stone, PH, 1980) |
| "The combination of nifedipine and prazosin was more successful in preventing myocardial damage in 16 patients with hypertension than was nifedipine alone in two other patients with hypertension." | 3.68 | Management of the cardiovascular manifestations of poisoning by the Indian red scorpion (Mesobuthus tamulus). ( Bawaskar, HS; Bawaskar, PH, 1992) |
| "Twenty patients with systemic sclerosis, Raynaud's phenomenon (19 of 20 patients), and clinically normal cardiac function underwent right heart catheterization." | 2.67 | Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. ( Kyriakidis, CA; Kyriakidis, MK; Mavrikakis, ME; Psarros, TK; Sfikakis, PP; Toutouzas, PK; Vergos, CG; Vyssoulis, GP, 1991) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent." | 2.45 | Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. ( Beckey, C; Lundy, A; Lutfi, N, 2009) |
| "High blood pressure is the most prevalent cardiovascular risk factor and, in clinical practice, coronary disease and hypertension often occur concurrently." | 2.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| "Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk." | 2.42 | Combined antihypertensive and lipid-lowering treatment. ( Cesari, M; Pessina, AC, 2004) |
| " Thus, amlodipine seems to provide a useful alternative to other agents currently available for the treatment of essential hypertension and chronic stable angina pectoris, with certain pharmacodynamic and tolerability properties that should be advantageous in many patients." | 2.38 | Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. ( Heel, RC; Murdoch, D, 1991) |
| "Verapamil was more often associated with conduction problems (up to 9%) and dyspnea or heart failure (up to 8%)." | 2.37 | Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy. ( Brouwer, RM; Bühler, FR; Follath, F, 1985) |
| " Diltiazem with a beta-blocker is usually well-tolerated, with a low incidence of adverse effects, similar to the experience with diltiazem monotherapy." | 2.37 | Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects. ( Parisi, AF; Strauss, WE, 1988) |
| "Nisoldipine is an orally administered calcium entry blocking drug structurally related to nifedipine." | 2.37 | Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. ( Friedel, HA; Sorkin, EM, 1988) |
| "In the treatment of preterm labor, the combination regimen of ritodrine and nifedipine can be more effective than ritodrine alone for prolonging gestation over seven days." | 1.40 | The influence of ritodrine alone or in combination with nifedipine on maternal cardiovascular side effects and pregnancy outcomes. ( Bae, JY; Hwang, I; Kim, MJ; Seong, WJ, 2014) |
| " Once-daily dosing with nifedipine GITS has been shown to achieve smooth and continuous blood pressure control, identical to conventional first-line diuretic therapy." | 1.33 | Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes. ( Heagerty, AM, 2005) |
| "Nisoldipine-treated rats showed no change in food consumption or body weight compared with control animals." | 1.30 | Cardioprotective and hypolipidemic effects of nisoldipine in the JCR:LA-cp rat. ( Amy, RM; Dolphin, PJ; Graham, SE; Russell, JC, 1997) |
| "The incidence of gingival hyperplasia has been reported as 10%-20% in patients treated with calcium antagonists in the general population." | 1.30 | Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients. ( Nakamoto, H; Okada, H; Shouda, J; Sugahara, S; Suzuki, H, 1999) |
| " Some calcium antagonists have been shown to alter digoxin kinetics and changes in digoxin dosage have been recommended." | 1.27 | The effect of nifedipine on serum digoxin concentrations in patients. ( Akers, S; Raizner, A; Schwartz, JB, 1984) |
| "They also have great potential for the treatment of hypertension, cerebrovascular disorders, and Raynaud's phenomenon." | 1.27 | Calcium channel blocking drugs. Part II: Clinical applications. ( Brill, DM; Fozzard, HA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (35.42) | 18.7374 |
| 1990's | 22 (22.92) | 18.2507 |
| 2000's | 29 (30.21) | 29.6817 |
| 2010's | 11 (11.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy, S | 1 |
| Jim, B | 1 |
| Shemesh, J | 1 |
| Motro, M | 1 |
| Grossman, C | 1 |
| Morag-Koren, N | 1 |
| Apter, S | 1 |
| Grossman, E | 1 |
| Imanishi, M | 1 |
| Ishizawa, K | 1 |
| Sakurada, T | 1 |
| Ishizawa, Y | 1 |
| Yamano, N | 1 |
| Kihira, Y | 1 |
| Ikeda, Y | 1 |
| Tsuchiya, K | 1 |
| Tamaki, T | 1 |
| Kim, MJ | 1 |
| Hwang, I | 1 |
| Bae, JY | 1 |
| Seong, WJ | 1 |
| Motaweih, AK | 1 |
| Usova, E | 1 |
| Hussain, W | 1 |
| Dello, Z | 1 |
| Schmidt, B | 1 |
| Petri, T | 1 |
| Sierra, C | 1 |
| Coca, A | 1 |
| Lundy, A | 1 |
| Lutfi, N | 1 |
| Beckey, C | 1 |
| Elliott, HL | 1 |
| Meredith, PA | 1 |
| van Mourik, MS | 1 |
| Cameron, A | 1 |
| Ewen, M | 1 |
| Laing, RO | 1 |
| Mancia, G | 5 |
| Parati, G | 2 |
| Bilo, G | 1 |
| Choi, J | 1 |
| Kilama, MO | 1 |
| Ruilope, LM | 4 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Konoshita, T | 1 |
| Makino, Y | 1 |
| Kimura, T | 1 |
| Fujii, M | 1 |
| Morikawa, N | 1 |
| Wakahara, S | 1 |
| Arakawa, K | 2 |
| Inoki, I | 1 |
| Nakamura, H | 1 |
| Miyamori, I | 1 |
| Dhaun, N | 1 |
| Melville, V | 1 |
| Blackwell, S | 1 |
| Talwar, DK | 1 |
| Johnston, NR | 1 |
| Goddard, J | 1 |
| Webb, DJ | 1 |
| Rayner, B | 1 |
| Buchanan-Lee, B | 1 |
| Brink, J | 1 |
| Opie, L | 1 |
| Rosenthal, T | 3 |
| Van Veenhuyzen, D | 1 |
| Coetzee, R | 1 |
| Heagerty, A | 1 |
| Deverly, A | 1 |
| Palmer, C | 1 |
| Kaplinsky, E | 1 |
| Salvetti, A | 2 |
| Wahlgren, NG | 1 |
| Funck-Brentano, C | 1 |
| Brown, M | 1 |
| Castaigne, A | 2 |
| de Leeuw, P | 1 |
| Palmer, CR | 1 |
| Wagener, G | 1 |
| Taddei, S | 1 |
| Ghiadoni, L | 1 |
| Fuchs, FD | 1 |
| Altura, BM | 1 |
| Kostellow, AB | 1 |
| Zhang, A | 1 |
| Li, W | 1 |
| Morrill, GA | 1 |
| Gupta, RK | 1 |
| Altura, BT | 1 |
| Yui, Y | 1 |
| Sumiyoshi, T | 1 |
| Kodama, K | 1 |
| Hirayama, A | 1 |
| Nonogi, H | 1 |
| Kanmatsuse, K | 1 |
| Origasa, H | 1 |
| Iimura, O | 1 |
| Ishii, M | 1 |
| Saruta, T | 1 |
| Hosoda, S | 1 |
| Kawai, C | 1 |
| Cesari, M | 1 |
| Pessina, AC | 1 |
| Yoshida, D | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Heagerty, AM | 1 |
| Weber, MA | 1 |
| Messerli, FH | 1 |
| Staessen, JA | 1 |
| Poole-Wilson, PA | 1 |
| Kirwan, BA | 1 |
| Vokó, Z | 1 |
| de Brouwer, S | 1 |
| Dunselman, PH | 1 |
| van Dalen, FJ | 1 |
| Lubsen, J | 1 |
| Shimokawa, H | 1 |
| Matsuoka, H | 1 |
| Yamagishi, S | 1 |
| Nakamura, K | 1 |
| Matsui, T | 1 |
| Karlsberg, RP | 3 |
| Ellrodt, AG | 1 |
| Singh, BN | 2 |
| Fossati, C | 1 |
| Guistiniani, S | 1 |
| Ellrodt, G | 1 |
| Chew, CY | 1 |
| Antman, EM | 3 |
| Stone, PH | 2 |
| Muller, JE | 2 |
| Braunwald, E | 2 |
| Fleckenstein, A | 1 |
| Zulik, R | 1 |
| Czinszky, L | 1 |
| Rossi, LP | 1 |
| Foster, BC | 1 |
| Schwartz, JB | 1 |
| Raizner, A | 1 |
| Akers, S | 1 |
| Assey, ME | 1 |
| Aronow, WS | 1 |
| Chia, BL | 1 |
| Ee, BK | 1 |
| Tan, AT | 1 |
| Choo, M | 1 |
| Schwartz, DJ | 1 |
| Wasserstrom, JA | 1 |
| Fozzard, HA | 2 |
| Lancelin, B | 1 |
| Blanchard, D | 1 |
| Aziza, JP | 1 |
| Guermonprez, JL | 1 |
| Maurice, P | 1 |
| Stoudemire, A | 1 |
| Bawaskar, HS | 3 |
| Bawaskar, PH | 3 |
| Figiel, GS | 1 |
| McDonald, L | 1 |
| LaPlante, R | 1 |
| Davies, RF | 1 |
| Goldberg, AD | 1 |
| Forman, S | 1 |
| Pepine, CJ | 1 |
| Knatterud, GL | 1 |
| Geller, N | 1 |
| Sopko, G | 1 |
| Pratt, C | 1 |
| Deanfield, J | 1 |
| Conti, CR | 1 |
| Russell, JC | 1 |
| Dolphin, PJ | 1 |
| Graham, SE | 1 |
| Amy, RM | 1 |
| Fernández Rodríguez, A | 1 |
| Camarasa García, F | 1 |
| Camino Calderón, E | 1 |
| Puras Tellaeche, A | 1 |
| Bohnemeier, H | 1 |
| Pinto, YM | 1 |
| Horkay, F | 1 |
| Tóth, M | 1 |
| Juhász-Nagy, A | 1 |
| Orzechowski, HD | 1 |
| Böhm, M | 1 |
| Paul, M | 1 |
| Grassi, G | 1 |
| Brown, MJ | 1 |
| de Leeuw, PW | 1 |
| Shouda, J | 1 |
| Nakamoto, H | 1 |
| Sugahara, S | 1 |
| Okada, H | 1 |
| Suzuki, H | 1 |
| García-López, FJ | 1 |
| de Alvaro, F | 1 |
| Avanzini, F | 1 |
| Tognoni, G | 1 |
| Fournier, A | 1 |
| Georgita, A | 1 |
| Bouffandeau, B | 1 |
| Oprisiu, R | 1 |
| Kjeldsen, SE | 2 |
| Westheim, AS | 1 |
| Os, I | 1 |
| Ruddy, MC | 1 |
| Baba, S | 1 |
| Hildebrandt, PR | 1 |
| Tuxen, CD | 1 |
| Lund-Johansen, P | 1 |
| Hansson, L | 1 |
| Omboni, S | 1 |
| Tam, IM | 1 |
| Wandres, DL | 1 |
| Opie, LH | 1 |
| Murdoch, D | 1 |
| Heel, RC | 1 |
| Kaesemeyer, WH | 1 |
| Prisant, LM | 1 |
| Carr, AA | 1 |
| Sfikakis, PP | 2 |
| Kyriakidis, MK | 1 |
| Vergos, CG | 1 |
| Vyssoulis, GP | 1 |
| Psarros, TK | 1 |
| Kyriakidis, CA | 1 |
| Mavrikakis, ME | 1 |
| Toutouzas, PK | 1 |
| Kloner, RA | 1 |
| Przyklenk, K | 1 |
| Brouwer, RM | 1 |
| Follath, F | 1 |
| Bühler, FR | 1 |
| Sorkin, EM | 2 |
| Clissold, SP | 1 |
| Brogden, RN | 1 |
| Brill, DM | 1 |
| Berman, BA | 1 |
| Ross, RN | 1 |
| Palombo, C | 1 |
| Mian, M | 1 |
| Bertelli, A | 1 |
| Revutskiĭ, EL | 1 |
| Konopleva, LF | 1 |
| Shevchuk, SG | 1 |
| Strauss, WE | 1 |
| Parisi, AF | 1 |
| Friedel, HA | 1 |
| Katz, AM | 1 |
| Leach, NM | 1 |
| Burgess, CD | 1 |
| Larach, DR | 1 |
| Zelis, R | 1 |
| Ferlinz, J | 1 |
| Winniford, MD | 1 |
| Hillis, LD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy[NCT01118286] | 4,497 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| A Multicenter Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies.[NCT00750113] | Phase 4 | 405 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| THE EFFECTS OF SITAXSENTAN ONCE DAILY DOSING ON PROTEINURIA, 24-HOUR BLOOD PRESSURE, AND ARTERIAL STIFFNESS IN SUBJECTS WITH CHRONIC KIDNEY DISEASE[NCT00810732] | Phase 2 | 27 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| [NCT00000478] | Phase 3 | 0 participants | Interventional | 1990-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Carotid-femoral pulse wave velocity (PWV), a measure of arterial stiffness, is determined from the time taken for the arterial pulse to propagate from the carotid to the femoral artery. Baseline was defined as the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period. (NCT00810732)
Timeframe: Baseline, Week 3 and 6
| Intervention | Meter per second (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 3 | Change at Week 6 | |
| Nifedipine | 7.94 | -0.21 | -0.38 |
| Placebo | 7.74 | -0.21 | 0.29 |
| Sitaxsentan | 7.97 | -0.19 | -0.41 |
Mean urine total protein assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Baseline was derived from an average of Week 0 (pre-dose) 24-hour urine collections prior to each treatment period. Week 6 was derived from an average of Week 6 24-hour urine collections for each treatment period. (NCT00810732)
Timeframe: Baseline, Week 6
| Intervention | Grams per 24 hours (Mean) | |
|---|---|---|
| Baseline | Change at week 6 | |
| Nifedipine | 1.95 | 0.01 |
| Placebo | 2.07 | -0.06 |
| Sitaxsentan | 2.07 | -0.62 |
The 24-hour ambulatory BP monitoring was performed by using a BP cuff which was attached to the participant's arm, using the same arm throughout the study, with a small monitor that comfortably sits in the pocket of participant. Mean values over 24-hour measurements at each measurement period were calculated. The change in total 24-hour ambulatory monitoring of systemic arterial BP, SBP and DBP at Week 3 and 6 relative to baseline were reported. Baseline was as an average of the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period. (NCT00810732)
Timeframe: Baseline, Week 3 and 6
| Intervention | Millimeter of Mercury (mmHg) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean Systemic Arterial BP: Baseline | Mean Systemic Arterial BP: Change at Week 3 | Mean Systemic Arterial BP: Change at Week 6 | Mean Systemic Arterial SBP :Baseline | Mean Systemic Arterial SBP: Change at Week 3 | Mean Systemic Arterial SBP: Change at Week 6 | Mean Systemic Arterial DBP: Baseline | Mean Systemic Arterial DBP: Change at Week 3 | Mean Systemic Arterial DBP: Change at Week 6 | |
| Nifedipine | 93.78 | -2.95 | -3.54 | 125.12 | -4.20 | -4.47 | 78.27 | -2.09 | -2.86 |
| Placebo | 92.98 | -1.20 | -0.35 | 125.17 | -2.81 | -1.57 | 77.58 | -0.86 | -0.41 |
| Sitaxsentan | 92.94 | -4.59 | -3.74 | 124.03 | -4.88 | -3.99 | 77.56 | -4.85 | -3.60 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
36 reviews available for nifedipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
[Drug development for cardiorenal disease based on oxidative stress control].
Topics: Animals; Cardiovascular Diseases; Humans; Nifedipine; Nitric Oxide; Nitroso Compounds; Oxidative Str | 2014 |
The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Cor | 2008 |
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Coronary | 2009 |
Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2011 |
Role of calcium channel blockers in the future, in view of the INSIGHT Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiova | 2002 |
Current treatment of patients with hypertension: therapeutic implications of INSIGHT.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; | 2003 |
Combined antihypertensive and lipid-lowering treatment.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Cardiovascular Diseases; Comorb | 2004 |
[Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
[ACTION study: efficacy of nifedipine in preventing cardiovascular disease in patients with coronary artery disease].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Coronary Disease; Coronary Vessels; Double-Blind | 2006 |
[STONE study and INSIGHT study: efficacy of nifedipine in the prevention of cardiovascular disease in hypertensive patients].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Humans; Hypertension; Nifedipine; Randomized Cont | 2006 |
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Calcium Channels; Cardiovascular Diseases; Cytokines; Diab | 2008 |
Clinical applications of slow channel blocking compounds.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Platelets; Blood Vessels; Calcium | 1983 |
[Side-effects of calcium antagonists].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Drug Hypersensitivity; Drug Interactions; Fendili | 1984 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B | 1980 |
History of calcium antagonists.
Topics: Aniline Compounds; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Gallopamil; | 1983 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
Topics: Benzazepines; Calcium Channel Blockers; Cardiovascular Diseases; Coronary Circulation; Diltiazem; He | 1980 |
The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Diuretics | 2001 |
[Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Bloc | 2001 |
Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS?
Topics: Amiloride; Arteriosclerosis; Calcium Channel Blockers; Cardiovascular Diseases; Diuretics; Drug Comb | 2002 |
Calcium-channel blockers and gingival hyperplasia.
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Female; Gingival Hyperplasia; Hu | 1992 |
Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Binding Sites; Calcium Channel Blockers; Calcium Channels; Card | 1991 |
Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1991 |
Progress in cardioprotection: the role of calcium antagonists.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Dogs; Humans; Nifedipine | 1990 |
Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Drug Ther | 1985 |
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Topics: Absorption; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Platelets; Calcium Channel | 1985 |
Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma, Exercise-Induced; Bronchial Spasm; Calcium; Ca | 1986 |
[Calcium antagonists: accounts on new perspectives of their use and an update on side effects].
Topics: Adult; Animals; Asthma; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Esophageal Ach | 1989 |
[Nifedipine in the treatment of diseases of the circulatory organs (a review of the literature)].
Topics: Blood Circulation; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Dr | 1989 |
Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Dil | 1988 |
Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Hypertension; Nifedipine | 1988 |
Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications.
Topics: Angina Pectoris; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Hemod | 1987 |
Advances in calcium blocker therapy.
Topics: Arrhythmias, Cardiac; Arteriosclerosis; Asthma; Blood Platelet Disorders; Calcium; Calcium Channel B | 1986 |
Nifedipine in myocardial ischemia, systemic hypertension, and other cardiovascular disorders.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Coronary Disease; Humans; Hypert | 1986 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
17 trials available for nifedipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina.
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; B | 2011 |
Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Moni | 2011 |
A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; Calcium Channel Blockers; Cardiovascular Diseases; | 2013 |
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.
Topics: Adult; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; | 2013 |
Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).
Topics: Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular D | 2003 |
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Asian People; Blood Pressure; Calcium Channel Blocke | 2004 |
Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Double-Blind Method; Drug Therap | 2007 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B | 1980 |
Vasodilators: scorpion envenoming and the heart (an Indian experience).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Bradycardia; Cardiovascular Diseases; Child; Ch | 1994 |
Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; Calcium Channel Blocker | 1997 |
The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic | 1998 |
Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiova | 1998 |
Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Disea | 2001 |
Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT).
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Blood Pressure Determination; Blood Pre | 2002 |
Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril.
Topics: Administration, Oral; Adult; Captopril; Cardiac Catheterization; Cardiovascular Diseases; Exercise T | 1991 |
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Topics: Absorption; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Platelets; Calcium Channel | 1985 |
[Nifedipine in the treatment of diseases of the circulatory organs (a review of the literature)].
Topics: Blood Circulation; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Dr | 1989 |
46 other studies available for nifedipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Progression of coronary artery calcification is associated with long-term cardiovascular events in hypertensive adults.
Topics: Adult; Aged; Calcinosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Vessels; Disease | 2013 |
The influence of ritodrine alone or in combination with nifedipine on maternal cardiovascular side effects and pregnancy outcomes.
Topics: Adult; Birth Weight; Calcium Channel Blockers; Cardiovascular Diseases; Cardiovascular System; Dose- | 2014 |
Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE).
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Therapy, Comb | 2015 |
Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data.
Topics: Antihypertensive Agents; Atenolol; Captopril; Cardiovascular Diseases; Cost of Illness; Developing C | 2010 |
Generic substitution--is it safe in patients at high cardiovascular risk?
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Drugs, Generic; Female; Humans; Hypertensio | 2002 |
Non-substitution of nifedipine slow-release preparations.
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Delayed-Action Preparations; Drugs, Generic; Huma | 2002 |
The role of the critical event committee in a major cardiovascular outcome study.
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; N | 2002 |
May we die twice?
Topics: Amiloride; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Complications | 2003 |
Expression of the nuclear factor-kappaB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis, and stroke.
Topics: Animals; Aorta, Thoracic; Biomarkers; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Di | 2003 |
Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes.
Topics: Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Therap | 2005 |
Safety of calcium antagonists: more ACTION.
Topics: Angina, Unstable; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Humans; Meta-An | 2005 |
Welcome--the calcium channel blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blocker | 1981 |
Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Coronary Disease; Diltiazem | 1980 |
Calcium channel blockers for cardiovascular disorders.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; | 1982 |
[The use of nifedipine (Corinfar) in hypertensive crises].
Topics: Adult; Aged; Blood Pressure; Brain Diseases; Cardiovascular Diseases; Female; Humans; Hypertension; | 1984 |
Calcium channel blockers. New treatment for cardiovascular disease.
Topics: Adult; Angina Pectoris; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiovascu | 1983 |
Calcium channel blockers: verapamil and nifedipine.
Topics: Calcium; Cardiovascular Diseases; Humans; Nifedipine; Verapamil | 1983 |
The effect of nifedipine on serum digoxin concentrations in patients.
Topics: Aged; Cardiovascular Diseases; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Humans | 1984 |
Calcium antagonists in the treatment of cardiovascular disease.
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine; Pyridines | 1983 |
Calcium blocker therapy in cardiovascular disease.
Topics: Adult; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; N | 1982 |
Calcium channel blockers: indications and limitations 1. Clinical pharmacology and use as antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Biological Availability; Calcium; Calcium Channel Blockers; Cardiovascular D | 1982 |
The current status of calcium antagonists in cardiovascular therapy.
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine; Verapamil | 1982 |
Therapeutic uses of calcium-blocking agents:verapamil, nifedipine, and diltiazem.
Topics: Benzazepines; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Humans; Nifedipine; Pyri | 1981 |
[Calcium inhibitors. Current indications in cardiology].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Diltiazem; Humans; Nifedipi | 1980 |
Cardiovascular morbidity and ECT.
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Comorbidity; Depressive Disorder; Drug Therapy, Combi | 1995 |
Cardiovascular complications of ECT.
Topics: Age Factors; Aged; Cardiovascular Diseases; Delirium; Depressive Disorder; Electroconvulsive Therapy | 1994 |
Revisiting calcium channel blockers--from basic facts to clinical practice.
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Humans; Hypertension; Nifedipine | 1996 |
Cardioprotective and hypolipidemic effects of nisoldipine in the JCR:LA-cp rat.
Topics: Animals; Blood Glucose; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Female; Hypoli | 1997 |
Long-Acting Nifedipine: End-Organ Protection and Prevention of Cardiovascular Disease. Proceedings of the 3rd International Symposium. Berlin, Germany, September 28, 1996.
Topics: Animals; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine; Vasodilator Agents | 1997 |
[Calcium antagonists, not long acting].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Nifedip | 1998 |
Endothelin converting-enzyme-1 mRNA expression in human cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspartic Acid Endopeptidases; Calcium Channel Blockers; Cardiovascular | 1998 |
Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Felodipine; Female; Gingival H | 1999 |
INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Di | 2000 |
INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases | 2000 |
INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2000 |
INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; C | 2000 |
Management of the cardiovascular manifestations of poisoning by the Indian red scorpion (Mesobuthus tamulus).
Topics: Adult; Aged; Animals; Cardiovascular Diseases; Child; Child, Preschool; Drug Therapy, Combination; F | 1992 |
Amlodipine in cardiovascular disease: the need for 24-hour protection and control. Proceedings of a meeting, Hong Kong, February 17, 1990.
Topics: Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1991 |
Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
Topics: Adrenal Gland Diseases; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; | 1991 |
Treatment of cardiovascular manifestations of human scorpion envenoming: is serotherapy essential?
Topics: Animals; Antivenins; Cardiovascular Diseases; Humans; India; Nifedipine; Prazosin; Scorpion Stings; | 1991 |
Calcium antagonism, new trends, aspects and long-term benefits. A symposium. Vancouver, Canada, May 1989.
Topics: Cardiovascular Diseases; Humans; Nifedipine | 1990 |
Calcium channel blocking drugs. Part II: Clinical applications.
Topics: Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Arrhythmias, Cardiac; Calcium Channel B | 1985 |
Calcium antagonists in cardiovascular disease: rationale for 24-hour action. Proceedings of an official satellite symposium and papers on amlodipine presented at the 25th Anniversary International Symposium on Calcium Antagonists in Hypertension. Basel, S
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1988 |
[Nifedipine, captopril and labetalol--overviews on the pattern of adverse effects].
Topics: Captopril; Cardiovascular Diseases; Drug Eruptions; Ethanolamines; Gastrointestinal Diseases; Humans | 1985 |
[Calcium channel blockers in circulatory system diseases. Proceedings of a conference of the Polish Society of Cardiology. Bydgoszcz, 17 May 1986].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1987 |
Calcium channel antagonists--cardiovascular therapy for the eighties?
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; | 1986 |